Multicenter phase II study of CPT-11 fractionated over two days with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer

Anticancer Research

Volumn 23, Issue 3 C, 2003, Pages 2903-2908

  Recchia, Francesco ^a,f,g   Nuzzo, A ^b   Lalli, A ^c   Di Lullo, L ^d   De Filippis, S ^a   Saggio, G ^a   Di Blasio, A ^b   Rea, S ^e,f  

^a Ospedale Civile di Avezzano   (Italy)

^b Ospedale Civile di Lanciano   (Italy)

^c Neurology Operative Unit   (Italy)

^d Ospedale Civile di Isernia   (Italy)

^e UNIVERSITY OF L'AQUILA   (Italy)

^f Fondazione Carlo Ferri   (Italy)

^g NONE   (Italy)

Author keywords

Camptothecin; Leucovorin; Metastatic colorectal cancer; S fluorouracil

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHRONOSEQUENCE; CLINICAL TRIAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIARRHEA; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG INFUSION; DRUG RESPONSE; DRUG SCREENING; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUTH DISEASE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SKIN TOXICITY; SURVIVAL TIME; THROMBOCYTOPENIA; TOXICITY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 0042123548     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Black RJ, Bray F, Ferlay J and Parkin DM: Cancer incidence and mortality in the European Union: Cancer registry data and estimates of national incidence for 1990. Eur J Cancer 33: 1075-1077, 1997.
2. Boring CC, Squires TS and Tong T: Cancer statistics 1. CA. Cancer J Clin 42: 19-38, 1992.
3. Advanced colorectal cancer meta-analysis project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10: 896-903, 1992.
4. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E and Bedenne L: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 15: 808-817, 1997.
5. Jaxel C, Kohn KW, Wani MC, Wall ME and Pommier Y: Structure-activity study of the action of camptothecin derivates on mammalian topoisomerse I: evidence for a specific receptor site and relation to antitumor activity. Cancer Res 49: 1465-1469, 1989.
6. Mullany S, Svingen PA, Kaufmann SH and Erlichman C: Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity. Cancer Chemother Pharmacol 42: 391-399, 1998.
7. Guichard S, Cussac D, Hennebelle I, Bugat R and Canal P: Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo. Int J Cancer 73: 729-734, 1997.
8. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C and Herait P: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352: 1413-1418, 1998.
9. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P and Jacques C: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352: 1407-1412, 1998.
10. O'Connel MJ: Irinotecan for colorectal cancer: A small step forward. Lancet 352: 1402, 1998.
11. Albigerges D, Chabot GG, Armand JP, Hérait P, Gouyette A and Gandia D: Phase I and pharmacologic studies of camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13: 210-221, 1995.
12. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
13. Hrynyuk W: The importance of dose intensity in the outcome of chemotherapy. In: Hellmann S, De Vita V, Rosemberg S (eds). Important Advances in Oncology. Philadelphia, PA, 121-141, 1988.
14. Simon R: Optimal two-stage design for phase II clinical trials. Control Clin Trials 10: 1-10, 1989.
15. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Ass 53: 457-481, 1958.
16. Recchia F, Rea S, Nuzzo A, Lalli A, Di Lullo L, De Filippis S, Saggio G, Di Blasio A, Massa E and Mantovani G: Multicenter phase II study of fractionated bimonthly oxaliplatin with leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer, pre-treated with chemotherapy. Oncol Rep 65: 65-70, 2003.
17. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alaki M, Gruia G, Awad L and Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first line treatment for metastatic colorectal cancer. A multicenter randomized trial. Lancet 355: 1041-1047, 2000.
18. Vamvakas L, Kakolyris S, Kouroussis C, Kandilis K, Mavroudis D, Ziras N, Androulakis N, Kalbakis K, Sarra E, Souglakos J and Georgoulias V, for the Greek Colorectal Cooperative Oncology Group. Irinotecan (CPT-11) in combination with infusional 5-Fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer. Am J Clin Oncol 25: 65-70, 2002.
19. Mans DR, Grivicich I, Peters GJ and Schwartsmann G: Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human carcinoma cell lines. Eur J Cancer 13: 1851-1861, 1999.
20. Rothenberg ML, Meropol NJ, Poplin EA et al: Mortalityassociated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19: 3801-3807, 2001.
21. Delioukina ML, Prager D, Parson M, Hecht JR, Rosen P and Rosen LS: Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma. Cancer 94: 2174-2179, 2002.
22. Scheithauer W, Rosen H, Kornek GV, Sebesta C and Depisch D: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 306: 752-755, 1993.
23. Recchia F, De Filippis S, Rosselli M, Saggio G, Piccinini M and Rea S: 5-Fluorouracil-carboplatin continuous infusion in advanced cancer. Tumori 87: 383-387, 2001.